Self‐reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first‐episode schizophrenia
Open Access
- 24 January 2023
- journal article
- research article
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 17 (10) , 974-983
Abstract
Aim: Many individuals with schizophrenia discontinue initially prescribed antipsychotics. Knowledge on reasons for discontinuation among individuals with first‐episode schizophrenia is sparse. We aimed to describe reasons for discontinuation and continuation, differences between individuals discontinuing and continuing, and factors predicting reasons for discontinuation or continuation.Methods: This was a prospective cohort study with a post hoc design. Individuals with first‐episode schizophrenia were included from early intervention teams in Denmark from 2009–2012. Sociodemographic and clinical variables were collected at baseline and reasons for discontinuation and continuation of antipsychotics were assessed at 3.5‐year follow‐up.Results: Among 215 patients, 76 reported reasons for discontinuation and 139 for continuation. The most frequent reasons for discontinuation were “side effects” and “patient believed he/she no longer needed the medication because he/she was now better”. The most frequent reasons for continuation were “benefits for positive symptoms” and “another person told them to”. Individuals who discontinued antipsychotics were at baseline younger, had longer DUP, less negative symptoms, better social function, lower compliance, higher self‐belief of coping, and fewer used antipsychotics compared to those continuing antipsychotics.Conclusions: The effect of antipsychotics is the main reason to continue, whereas side effects were the main reason to discontinue. Knowledge of reasons to discontinue or continue is helpful in shared decision‐making, identifying individuals with high odds of discontinuation, improving adherence, and helping with safe discontinuation.Keywords
Funding Information
- TrygFonden (109436, 7‐10‐1057)
This publication has 39 references indexed in Scilit:
- Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuationPatient Preference and Adherence, 2012
- Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and cliniciansPatient Preference and Adherence, 2011
- Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectivesCurrent Medical Research and Opinion, 2010
- International Consensus Study of Antipsychotic DosingAmerican Journal of Psychiatry, 2010
- Predictors of poor adherence to medication among patients with first‐episode schizophrenia‐spectrum disorderEarly Intervention in Psychiatry, 2009
- Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophreniaSchizophrenia Research, 2008
- Register-based follow-up of social benefits and other transfer payments: Accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based surveyScandinavian Journal of Public Health, 2007
- Remission in Schizophrenia: Proposed Criteria and Rationale for ConsensusAmerican Journal of Psychiatry, 2005
- Development and validation of the Working Alliance Inventory.Journal of Counseling Psychology, 1989
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987